Forschungsdatenbank

Projektübersicht
Login
Suche

Barton

Fakultäten » Vetsuisse-Fakultät » Labortierkunde, Institut für » Prof. Dr. Matthias Barton » Barton

Current research project

Title / Titel Role of aging for the pathogenesis of obesity-associated diseases
PDF Abstract (PDF, 14 KB)
Original title / Originaltitel Die Bedeutung des Alterungsprozesses bei der Entstehung Übergewichts-bedingter Erkrankungen
Summary / Zusammenfassung Obesity and aging are both major determinants of disease in humans. The physiopathology of diseases associated with both conditions such as hypertension, cancer, glomerulosclerosis, and atherosclerosis shares a number of common pathways, which include oxidative stress and accelerated cell growth. This project is aimed to characterize metabolic changes and pathways in the cardiovascular system in youth and aging, and to identify changes that are specific for either aging or obesity. It is anticipated to identify new approaches for the treatment of physiopathologies specific to each of the two conditions.

Supported by SNSF grants Nr. 58 421, Nr. 58 426, Nr. 108 258 and Nr. 122 504
Weitere Informationen
Publications / Publikationen Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension, 36, 451-461, 2018

Obesity causes lymphatic vascular injury: time for clinical translation
M. Barton, M. Husmann
J Physiol (Lond) 594, 6807-6808, 2016

Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016

Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016

Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016

Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015

Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014

Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretalla, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci 118, 206-212, 2014

Regulation of vascular smooth muscle tone by Adipose-Derived Contracting Factor
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
PLoS ONE 8, e79245, 2013

Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton
Curr Opin Pharmacol 13, 149-153, 2013

Childhood obesity: Preventing today's children from becoming tomorrow's patients 
M. Barton
IFAVA Scientific Newsletter 75, 1, 2013

Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013

Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012

Childhood obesity: a life-long health risk
M. Barton
Acta Pharmacol Sin 33, 189-193, 2012

Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012

Obesity and risk of vascular disease: Importance of endothelium-derived vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol epub May 10, 2011

Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan
Contrib Nephrol 172, 255-260, 2011

Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib Nephrol 172, 120-138, 2011

Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton
Contrib Nephrol 172, 210-222, 2011

Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010

Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010

Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis.
M. Barton.
Pflügers Arch 460, 825-837, 2010

Getting radical with obesity - new links between fat and heart disease
M. Barton, E. Haas, I. Bhattacharya.
Arterioscler Thromb Vasc Biol 29, 447-448, 2009

Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009

Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik.
M. Husmann, M. Keller, M. Barton.
Swiss Med Forum 50, 1008-1011, 2008

Dietary fat intake and cardiovascular response
M. Damjanovic, M. Barton.
Curr Hypertens Rep 10, 25-31, 2008

Reversal of proteinic renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008

Endothelin stimulates vascular hydroxyl radical formation. Effects of obesity.
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K. Baumann, M. Barton.
Am J Physiol Regul Integrat Comp Physiol 293, R2218-R2224, 2007

Management and prevention of obesity-associated hypertension.
M. Barton.
Ren Angiotens Syst Cardiovasc Med 1, 11-14, 2005

Aging and biomedicine 2005: Where should we go from here?
M. Barton.
Cardiovasc Res 66, 187-89, 2005

Cardiovascular consequences of the obesity pandemic: need for action.
M. Barton, J. Furrer. Exp Opin Invest Drugs 12, 1757-1759, 2003

Obesity-associated activation of angiotensin and endothelin in the cardiovascular system.
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T. Traupe.
Int J Biochem Cell Biol, 35, 826-837, 2003

Weitere Informationen

Project leadership and contacts /
Projektleitung und Kontakte
Prof. Dr. Matthias Barton (Project Leader) barton@access.uzh.ch
Dr Matthias Meyer  
Dr. Oliver Baretella  
Funding source(s) /
Unterstützt durch
SNF (Personen- und Projektförderung), Foundation, Others
 
In collaboration with /
In Zusammenarbeit mit
Prof. K. Amann, University of Erlangen Germany
Prof. R. Brandes, University of Frankfurt Germany
Prof. R. Hofmann-Lehmann, University of Zurich Switzerland
Duration of Project / Projektdauer Jul 2006 to Dec 2020